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Abstract
Objectives: Both excessive and insufficient angio-
genesis are associated with progression of diabetic
complications, of which poor angiogenesis is an
important feature. Currently, adipose-derived stem
cells (ADSCs) are considered to be a promising
source to aid therapeutic neovascularization. How-
ever, functionality of these cells is impaired by dia-
betes which can result from a defect in hypoxia-
inducible factor-1 (HIF-1), a key mediator involved
in neovascularization. In the current study, we
sought to explore effectiveness of pharmacological
priming with deferoxamine (DFO) as a hypoxia
mimetic agent, to restore the compromised angio-
genic pathway, with the aid of ADSCs derived
from streptozotocin (STZ)-induced type 1 diabetic
rats (‘diabetic ADSCs’).
Materials and methods: Diabetic ADSCs were trea-
ted with DFO and compared to normal and non-
treated diabetic ADSCs for expression of HIF-1a,
VEGF, FGF-2 and SDF-1, at mRNA and protein
levels, using qRT-PCR, western blotting and
ELISA assay. Activity of matrix metalloproteinases
-2 and -9 were measured using a gelatin zymogra-
phy assay. Angiogenic potential of conditioned
media derived from normal, DFO-treated and non-
treated diabetic ADSCs were determined by
in vitro (in HUVECs) and in vivo experiments
including scratch assay, three-dimensional tube for-
mation testing and surgical wound healing models.
Results: DFO remarkably enhanced expression of
noted genes by mRNA and protein levels and
restored activity of matrix metalloproteinases -2
and -9. Compromised angiogenic potential of con-
ditioned medium derived from diabetic ADSCs was
restored by DFO both in vitro and in vivo experi-
ments.
Conclusion: DFO preconditioning restored neovas-
cularization potential of ADSCs derived from dia-
betic rats by affecting the HIF-1a pathway.
Introduction
Impaired angiogenesis plays a pivotal role in the patho-
genesis of a variety of disorders such as diabetes melli-
tus (DM) (1,2). Inadequate neovascularization of the
skin, nerves and myocardium clinically translates into
the major manifestations of diabetes, including impaired
wound healing, neuropathy and poor prognosis after
myocardial infarction (3,4). In this setting, therapeutic
angiogenesis is an ideal option towards restoring normal
circulation in many human diseases, particularly DM.
Recently, adult stem cell-based medicine has been
shown to be a promising therapeutic strategy, facilitating
repair of diabetic ischaemic tissues (5). Some criteria
among others, make ADSCs attractive candidates for
use in cell therapies. ADSCs are multipotent mesenchy-
mal stromal cells (MSCs), which are easily accessible,
easy to culture to high numbers and able to self-renew
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and differentiate into various cell types, in particular
endothelial cells and vascular myocytes (6,7). Moreover,
autologous ADSCs, due to their secretion of many
potent angiogenic factors and not being subject to
immune rejection, have been considered to be excellent
choice for curative neovascularization treatment (8–10).
However, previous reports have indicated that ADSCs
fron a diabetic source, compared to normal ADSCs,
exhibit poor and insufficient angiogenic induction
(11,12). Clinically, such an obstacle may prevent appli-
cation of autologous diabetic ADSCs. There is, thus, a
need to identify and revive intrinsic impaired mecha-
nisms before cell implantation.
It has also been demonstrated that hypoxia-inducible
factor-1 (HIF-1) transcriptional complex regulates a
wide range of hypoxia-induced cell processes including
angiogenic factor production in ADSCs (13,14). The
HIF-1 transcriptional complex plays a central role in cell
responses when oxygen availability changes; it is com-
posed of a hypoxia-regulated alpha subunit and a stable
beta subunit (15). Under normoxic conditions, the HIF-
1a subunit rapidly becomes hydroxylated by HIF prolyl-
hydroxylases (PHDs), followed by ubiquitination and
proteasomal degradation. PHDs enzymes belong to the
oxygenase superfamily, which needs iron and 2-oxoglu-
tarate as cofactors (16–18). In normoxia, use of an iron-
chelating agent causes enzyme inhibition, leading to
HIF-1a stabilization. HIF-1, through binding to hypoxia
response elements (HREs), can up-regulate expression
of several angiogenic genes such as vascular endothelial
growth factor (VEGF), stromal cell-derived factor 1
(SDF-1), fibroblast growth factor-2 (FGF-2) and matrix
metalloproteinases (MMPs)-2 and -9 (19,20). MMPs are
extracellular endoproteinases secreted by MSCs, and
play important roles during angiogenesis. They facilitate
migration of endothelial cells by disrupting extracellular
matrix (ECM), and can also release angiogenic factors
including VEGF and FGF-2 from the ECM. Several
MMPs particularly, MMP-2 and -9, have been recog-
nized as being more involved in proceeding to angio-
genesis (21,22).
To date, different strategies have been proposed to
promote functional capacity of impaired stem cells by
affecting the HIF-1a pathway, including preconditioning
of stem cells with hypoxic shock (23) and pharmacologi-
cal agents that mimic hypoxia (24,25). DFO is an iron-
chelating agent used clinically in cases of iron overload,
such as thalassaemia (26). It inhibits the HIF prolyl-
hydroxylases and can stabilize HIF-1a through its iron-
chelating activity. Thus, DFO acts as a hypoxia mimetic
agent in normoxia (27). In this respect, accumulating evi-
dence has shown that DFO can increase VEGF secretion
from ADSCs from non-diabetic sources and bone marrow
mesenchymal stem cells (BMSCs) from non-diabetic
sources, via the HIF-1a pathway (13,28). We, thus,
sought to evaluate effects of DFO preconditioning on
restoring angiogenic potential of ADSCs derived from
STZ-induced diabetic rats to enhance efficacy of cell ther-
apy in DM, both in vitro and in vivo.
Material and methods
Antibodies and reagents
Polyclonal antibodies against FGF-2 and SDF-1 were
from Abcam (Cambridge, UK). Fluorescein isothio-
cyanate (FITC)-conjugated anti-rat antibodies against
CD45, CD90, FITC-conjugated mouse IgG isotype con-
trol, purified mouse IgG isotype control and purified
anti-rat antibody to CD73 were purchased from BD Bio-
science and eBioscience (San Diego, CA, USA). FITC-
conjugated CD11b antibody was obtained from Gene-
Tex, Inc. (United States) and FITC-conjugated anti-rat
CD44 and CD31 were purchased from Serotec (Oxford,
UK). HIF inhibitor was from Santa Cruz Biotechnology
(San Jose, CA, USA) and rat VEGF Quantikine
enzyme-linked immunosorbent assay (ELISA) kit was
from R&D Systems. Monoclonal antibodies against
HIF-1a, DFO, gelatin A and B, streptozotocin, protease
and phosphatase inhibitor cocktails, collagenase type I
and MTT were purchased from Sigma (Sigma Aldrich,
St Louis, MO, USA). Minimal essential medium a
(aMEM), foetal bovine serum (FBS) and penicillin-
streptomycin were from Gibco (Invitrogen, Carlsbad,
CA, USA) and Trizol reagent was from Invitrogen
(Merelbeke, Belgium). Oligo (dT) primer, moloney mur-
ine leukaemia virus reverse transcriptase (M-MLV RT)
and Maxima SYBR Green/ROX qPCR Master Mix (2X)
were purchased through Fermentas (UK). Horseradish
peroxidase-linked anti-rabbit secondary antibody and
anti-glyceraldehyde-3-phosphate dehydrogenase antibody
(GAPDH) were obtained from Cell Signaling (Danvers,
MA, USA). Cytodex 3 microcarrier bead was from
Amersham Pharmacia Biotech (UK) and Amicon Ultra-
15 Centrifugal Filter Unit with Ultracel-3 membrane
was from Millipore.
Experimental animals
Male Wistar rats aged 8–10 weeks, weighing 200–250 g
were purchased from the animal facility of the Pasture
Institute of Iran. They were maintained in standard con-
ditions (individual plastic cages, temperature 20–26 °C
and humidity of 40–70%, with regular light cycles of
12/12 h light/dark). The study was accepted by the Ethi-
cal Committee of Tehran University of Medical Sciences
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and was performed in accordance with its guideline base
on the National Institutes of Health Principles of Labo-
ratory Animal Care (NIH publication no. 85-23, revised
1985).
Induction of diabetes
Twenty rats were classified randomly into two groups:
normal group (n = 10) and diabetic group (n = 10).
Diabetes was induced in rats of the diabetic group by a
single intraperitoneal injection of streptozotocin (STZ)
(55 mg/kg). One week after injection, blood glucose
levels were measured. Only animals with blood glucose
levels >300 mg/dl were included in the study. Over the
next 4 months, blood glucose was measured twice every
month to ensure that its level was over 300 mg/dl.
ADSC isolation
All procedures were performed under sterile conditions.
First, rats were euthanized using ketamine/xylazine over-
dose. After shaving abdominal hair, skin was cleansed
using povidone-iodine solution. Epididymal fat-pads
were excised from diabetic and non-diabetic (normal)
animals and were soaked in phosphate-buffered saline
(PBS) containing 5% penicillin/streptomycin and
antimycotic agent. Debris was removed, fat tissues were
minced, and washed extensively in PBS to remove
haematopoietic cells. For isolation of ADSCs, adipose
tissues were exposed to 0.075% collagenase type I pre-
pared in aMEM containing 2% penicillin/streptomycin
under gentle agitation for 30 min at 37 °C. Collagenase
was neutralized with growth medium (aMEM containing
15% FBS and 1% penicillin/streptomycin) and the mix-
ture was centrifuged at 2000 rpm for 6 min. After dis-
carding supernatants, pellets were suspended in 1 ml
ice-cold lysis buffer for 10 min and subsequently
washed in PBS. Growth medium was added to pellets
and filtered using a 100 lm nylon mesh. Filtered frac-
tions were incubated in a humidified chamber with 5%
CO2 atmosphere at 37 °C. Adherent cells at third pas-
sages were used as ADSCs in the next steps (7).
Characterization of ADSCs
ADSC surface marker expressions were evaluated using
fluorescence-activated cell sorting (FACS) analysis with a
FACS Calibur cytometer (Becton Dickinson, San Diego,
CA, USA). Briefly, cultured ADSCs from three to four
passages were pelleted and washed three times in PBS.
Afterwards 2 9 105 cells were incubated in saturated
concentration of FITC-conjugated anti-rat antibodies
against CD11b, CD31, CD44, CD45, CD90 and purified
CD73 for 40 min at 4 °C in the dark. FITC-unconjugated
antibody was incubated with secondary conjugated anti-
body for 15 min. Mouse IgG isotype served as negative
control. Cells were centrifuged for 6 min and resuspended
in PBS. Finally, results were analysed using Cell Quest
software and compared to isotype control.
Colony-forming unit (CFU) assay
CFU assay was used to compare size and number of
colonies derived from normal and diabetic ADSCs.
Appropriate numbers of cells at early passages were
seeded in six-well plates. Growth medium was changed
every 3–4 days and after 2 weeks, dishes were washed
in 10–15 ml PBS. Then, colonies were fixed and stained
with 5 ml 0.5% crystal violet solution in methanol for
30 min. After rinsing in PBS, numbers and sizes of
colonies were determined using NIH ImageJ software
(http://rsbweb.nih.gov/ij). Colonies with a minimum of
50 cells were included.
Quantification of intracellular iron by atomic absorption
spectroscopy
Cultured ADSCs (passage 3) were pelleted and washed
three times in cold PBS. Next, 1 9 106 cells were lysed
with 500 ll of 50 mM NaOH for 2 h on a shaker. Cell
lysates were used for quantification of total amount of
iron, using atomic absorption spectroscopy (Varian
SpectrAA-600 Atomic Absorption Spectrometer with
GTA 100). Intracellular iron concentration was reported
as iron (pg) per cell.
Preparation of different concentrations of DFO
DFO was dissolved in distilled water and kept at 4 °C.
Required concentrations of DFO (75, 150, 300 lM) were
prepared from the stock solution. HIF-1 inhibitor was
used according to the manufacturer’s instructions.
Briefly, 30 lM HIF-1 inhibitor was used 1 h before pre-
treatment of ADSCs with 300 lM DFO.
MTT assay
The MTT assay is one of the most frequently used col-
orimetric assays for determining cell viability. Activity
of mitochondrial dehydrogenases in viable cells leads to
reduction of tetrazolium salts to dark blue formazan.
Briefly, normal ADSCs (nADSCs) and diabetic ADSCs
(dADSCs) were seeded into 96-well microplates at
10,000 cells per well. Final reaction products of
nADSCs and dADSCs were measured after 24, 48 and
72 h. For evaluation of cytotoxic effects of DFO on
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dADSCs, cells were seeded into 96-well microplates;
after 24 h, they were exposed to different concentrations
of DFO (0, 75, 150, 300 lM). After 24, 48 and 72 h,
MTT solution was added into each well and plates were
incubated for 4 h at 37 °C in the dark. Medium was
removed and dimethylsulphoxide (DMSO) (100 ll)
was added to each well. Absorbance of the solution was
measured at 570 nm using a microplate reader (Bio-Tek
ELX800, Winooski, VT, USA).
Real-time PCR
Normal, non-treated and treated diabetic ADSCs after
exposure to DFO, were used for total RNA extraction, by
utilization of Trizol reagent according to the manufac-
turer’s protocols. Then, RNA quality and concentration
were evaluated spectrophotometerically. Complementary
DNA was synthesized by 1 ll M-MLV RT, 1 ll deoxyri-
bonucleotide triphosphates (dNTPs), 0.5 ll RNase Inhibi-
tor, 2 ll oligo (dT) primer and 3 lg RNA in final volume
of 20 ll. The mixture was incubated for 1 h at 42 °C, fol-
lowed by incubation at 72 °C for 10 min. Quantitative
reverse transcription-polymerase chain reaction (qRT-
PCR) was performed using the Rotor-Gene 6000 System
(Corbett Research). Reaction mixture contained cDNA
template, 15 ll the Maxima SYBR Green/ROX qPCR
Master Mix and specific primers (Table 1). GAPDH was
used as endogenous control gene. Thermal cycling profile
was as follows: Initial denaturation at 95 °C for 10 min,
and 40 cycles of denaturing at 95 °C for 15 s, annealing
at 60 °C for 30 s and extension for 30 s at 72 °C. Thresh-
old cycle (Ct) was determined for GAPDH and target
genes of each sample. DCt was calculated for each sample
and relative gene expressions were calculated.
Western blot analysis
Non-treated and treated cells were trypsinized, and
washed centrifugally twice, in cold PBS. Cells were
lysed using ice-cold lysis buffer containing a protease
and phosphatase inhibitor cocktail and centrifuged for
30 min, 12,000 g at 4°C. Total protein concentration
was determined using the Bradford method (29). Equal
concentration of samples (150 lg) was loaded and
separated on SDS-PAGE gel. Next, proteins were trans-
ferred to nitrocellulose membranes followed by incuba-
tion with primary antibodies overnight at 4 °C.
Antibodies included mouse monoclonal anti-HIF-1a
(1:500), rabbit polyclonal anti-FGF-2 (5:1000), rabbit
anti-SDF-1 (2.5:1000) and rabbit anti-GAPDH (1:5000).
After this step, membranes were incubated with sec-
ondary antibody (anti-mouse or anti-rabbit conjugated to
horseradish peroxidase) for 1 h at 4 °C. An enhanced
chemiluminescence kit was used to visualize protein
bands which were then quantified by densitometry,
using Total Lab software (UK).
Preparation of conditioned media
After reaching 80% confluence, cultured ADSCs (in six-
well plates) were rinsed in PBS and fed with 3 ml
serum-free medium. After 24 h, supernatants were col-
lected and frozen at 80 °C until the following step.
For in vivo experiments, conditioned medium (CM) was
concentrated (50-fold) by ultra-filtration centrifugal filter
units, with 3 kD cut-off, according to the manufacturer’s
instructions. For collecting CM from pre-treated ADSCs,
cells were treated with DFO (150 and 300 lM) and/or
HIF-1 inhibitor, for 24 h then washed in PBS several
times. Then they were incubated with serum-free med-
ium and supernatant was collected after 24 h.
ELISA assay for release of VEGF
VEGF concentration was measured in 50 ll different
culture media (CM) from standards in 0 to 2000 pg/ml
range, using an ELISA kit, according to the manufac-
turer’s instructions. VEGF expression was normalized to
protein concentration.
Gelatin zymography
A zymography assay was used to analyse effects of
DFO on activities of matrix metalloproteinases (MMPs)-
2 and -9, in nADSCs and dADSCs. CM were prepared
as described above and subjected to zymographic assay.
Table 1. Rat primers for qRT-PCR
Gene Sense strand Antisense strand Size of product
VEGF GTGTGTGTGTGTATGAAATCTGTG GCAGAGCTGAGTGTTAGCAA 107 bp
FGF-2 TCCAAGCAGAAGAGAGAGGAG GGCGTTCAAAGAAGAAACAC 129 bp
SDF-1 AAACTGTGCCCTTCAGATTG GGCTTTGTCCAGGTACTCTTG 100 bp
GAPDH ACA GTC CAT GCC ATC ACT GCC TGC TTC ACC ACC TTC 266 bp
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Briefly, supernatants were mixed with 3X loading buffer
(125 mM Tris-HCl, 20% glycerol, 2% SDS and 0.002%
bromophenol blue, pH 6.8). Mixtures were separated
electrophoretically using 10% polyacrylamide gel, in the
presence of 0.1% SDS containing 0.1% gelatin A
(MMP-2) or B (MMP-9). Then, gels were soaked in Tri-
ton X-100 for 60 min and incubated in developing buf-
fer (50 mM Tris-HCl, 200 mM NaCl, 5 mM CaCl2 and
0.01% NaN3, pH 7.5) overnight at 37 °C. Subsequently
gels were stained with Coomassie Blue solution (0.1%
Coomassie Brilliant Blue G-250, 40% methanol, 10%
acetic acid and deionized water) and then destained with
40% methanol, 10% acetic acid and deionized water.
When enzyme-digested regions were visualized as white
bands against a blue background, gels were pho-
tographed and bands were quantified using densitometric
analysis from Total Lab software.
In vitro scratch assay
The scratch assay is a straightforward method to evaluate
cell migration in vitro. HUVECs were obtained from the
Pasteur Institute (Tehran, Iran). They were loaded into
six-well plates, all at the same density, and then 5 ml
growth medium was added to each well. After reaching
90% confluence, scratch wounds were created in the cell
monolayers by scraping them with a sterile 1000 ll pip-
ette tip. After removal of detached cells by washing in
PBS, cells were fed CM derived from treated and non-
treated cells. The HUVECs were then incubated to allow
cells to migrate into the scratch area. The next step was
capturing photographic images during cell migration
(from five random, separate, microscopic fields) and ana-
lysing them using NIH Image J software (30).
HUVEC capillary tube formation in three-dimensional
collagen gel
The HUVECs were mixed with Cytodex 3 microcarrier
beads and placed in an incubator at 37 °C and the
mixed suspension was flicked every 20 min to allow for
uniform distribution of cells on the microcarrier beads.
Beads were seeded in 12-well plates and then incubated
overnight at 37 °C. On the following day, cell-coated
beads were embedded in ice-cold collagen matrix and
serum-free medium and the mixture was loaded into 96-
well plates and allowed to solidify for 45 min at 37 °C.
Next, serum-free medium, and CM derived from normal,
DFO-treated and non-treated diabetic ADSCs were
added to wells. Cells were photographed after 48 h.
Sprout formation was analysed using NIH Image J soft-
ware according to the standard method, and are pre-
sented as percentages of control (31).
Wound healing model
Forty-eight male Wistar rats were randomly divided into
four groups as follows: treated with serum-free media,
those treated with CM derived from diabetic rats, normal,
and 300 lM DFO-treated ADSCs. Excisional wounds were
created in the splinting model, as described previously (8).
In brief, following administration of anaesthesia (intramus-
cular injection of xylazine and ketamine), dorsal areas of
rats were shaved and one 8 mm full-thickness excisional
skin wound, per animal, was created in the midline of the
neck. Wounds were injected with 100 ll concentrated
medium and concentrated CM derived from normal,
300 lM DFO-treated and non-treated diabetic ADSCs
(60 ll around the wound and 40 ll into the wound bed).
The animals were housed individually for 2 weeks.
Wound area analysis
Digital photographs of wounds were captured after cre-
ating during healing. Wound areas were blindly mea-
sured in mm2 squares, using NIH Image J software.
Then, wound closure rates were calculated using the fol-
lowing formula (32):
Wound closure rate (%)
¼ ðWound area on day 0Wound area on day xÞ=
Wound area on day 0 100
x ¼ 0; 3; 7; 10; 14
Histological examination
Rats were sacrificed on days 3, 7, 10 and 14 and skin sam-
ples, including wounds plus 10 mm of surrounding skin,
were collected for histological examination. Skin speci-
mens were fixed in 10% formalin solution and embedded
in paraffin wax blocks. Afterwards, 3 lm sections were
stained with Masson’s trichrome for collagen fibre stain-
ing and haematoxylin and eosin (H&E). Angiogenesis,
epithelialization, collagen levels and macrophage counts
were evaluated by examining three fields per section of
the wounds at 100x and 400x magnification. Each sample
was given a histological score using Abramov’s histologi-
cal scoring system (33) as summarized in Table 2.
Statistical analysis
Statistical significance of mean differences between groups
was analysed by one-way or repeated ANOVA with
Tukey’s post-test, and two-way ANOVA with Duncan and
Bonferroni post-test, as appropriate. Unpaired Student’s
t-testing was performed for comparisons between two
groups (diabetic and normal ADSCs). Statistically,
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differences were assumed significant at P < 0.05. Results
are presented as mean  standard error of the mean
(SEM).
Results
ADSC characterization and morphology of diabetic and
normal ADSCs
Flow cytometry indicated that ADSCs (passage 3–4)
were positive for CD90, CD73 and CD44 and were neg-
ative for haematopoietic and endothelial lineage markers
CD11b, CD31 and CD45 (Fig. 1a). The cells had
fibroblast-like morphology at this passage level. Mor-
phologically, dADSCs had more flattened appearances
compared to nADSCs of the same passage (Fig. 1b).
CFU assay and iron content of diabetic and normal
ADSCs
CFU assays revealed that dADSCs formed significantly
lower numbers of colonies (6.9  0.4%) than nADSCs
(11.66  0.7%) (P < 0.01). Also, colonies derived from
dADSCs significantly were smaller (P < 0.001) than
those derived from normal cells (Fig. 2a,b). Basal total
iron content was found to be 0.041  0.002 and
0.046  0.001 pg iron per cell for nADSCs and
dADSCs respectively (n = 3). There were no significant
differences between means of iron content of diabetic
ADSCs and normal ADSCs (Fig. 2c).
DFO, by MTT assay, showed no cytotoxic effect after
24 h
Cell viability was evaluated by MTT assay; nADSCs
seemed to be more proliferative than dADSCs after 72 h
Table 2. Histological score based on Abramov’s histological scoring
system (33)
Scores Collagen
level
Epithelialization Angiogenesis Macrophages
0 None None None –
1 Scant Partial 1–5 0–25
2 Moderate Complete,
but immature
or thin
6–10 26–50
3 Abundant Complete
and mature
≥10 >51
(a)
(b)
I II
Figure 1. Characterization and morpho-
logical assessment of ADSCs. (a) Flow
cytometry showed that the ADSCs were neg-
ative for CD45, CD11b and CD31 but posi-
tive for CD44, CD73 and CD90. Data are
shown as a histogram plot, with black repre-
senting isotype control and white demonstrat-
ing experiments. (b) Assessment of
morphology of ADSCs demonstrated that (I)
diabetic ADSCs had more flattened and
rounder morphology than (II) normal ADSCs.
Dashed lines indicate cells.
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(P < 0.01; Fig. 3a). Pre-treatment of dADSCs with
DFO (75, 150 and 300 lM) revealed no cytotoxic effect
after 24 h (Fig. 3). The results demonstrate that DFO
(150 lM) seemed to increase proliferation of ADSCs
compared to non-treated dADSCs after 24 h (P < 0.01;
Fig. 3c). On the other hand, DFO significantly caused
cytotoxic effects after 48 and 72 h (P < 0.05; Fig. 3).
Hence, DFO was applied at concentrations of 150 and
300 lM for 24 h in all other experiments of this study.
DFO preconditioning enhanced HIF-1a protein
expression in diabetic ADSCs
Western blotting assay was used to compare HIF-1a
protein expression in nADSCs, DFO-treated and non-
treated dADSCs. The results indicated that non-treated
dADSCs had significantly lower HIF-1a protein expres-
sion levels compared to nADSCs (P < 0.001). HIF-1
expression was enhanced in dADSCs at 150 (P < 0.01)
and 300 lM (P < 0.001) concentration of DFO in a
concentration manner, so that non-significant changes
were detected between normal group and treated groups.
This effect was remarkably reversed by pre-treatment
with 30 lM of HIF-1 inhibitor 1 hour before exposure
to 300 lM DFO (P < 0.001) (Fig. 4a). HIF-1a expres-
sion was also assessed in dADSCs pre-treated with
150 lM DFO over the appropriate time period (0, 6, 12,
24 h). DFO significantly increased HIF-1a expression
after 12 h (P < 0.05) and to a highest level after 24 h
(P < 0.001), before showing cytotoxic effects (Fig. 4b).
Therefore, DFO was applied for 24 h in all other experi-
ments of this study.
DFO enhanced VEGF, FGF-2 and SDF-1 mRNA
expression levels
Quantitative real-time PCR was performed on nADSCs,
DFO-treated and non-treated dADSCs and results indicated
(a)
I II
(b)
(c)
I II
Figure 2. Colony formation and iron
assessment of ADSCs. (a) Representative
images of colonies of diabetic ADSCs (I) and
normal ADSCs (II) by light microscopy. (b)
Assessment of size (I) and number (II) of
colonies derived from diabetic and normal
ADSCs, by NIH imageing. (c) Assessment of
iron content of normal and diabetic ADSCs.
Data are represented as mean  SEM (n = 3,
**P < 0.01, ***P < 0.001 versus normal
cells). Statistical significance was measured
by unpaired Student’s t-test.
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that for all genes, dADSCs had significant reduction in
related mRNA levels, compared to nADSCs, so that
VEGF, SDF-1 and FGF-2 expression levels were
0.13  0.01 (P < 0.001), 0.07  0.001 (P < 0.001) and
0.01  0.008 (P < 0.01) times lower in dADSCs respec-
tively. In treated subgroups with 150 and 300 lM concen-
trations DFO, expression levels of VEGF were estimated
to be in the order of 0.42  0.01 times (P < 0.001) and
1.36  0.1 times (P < 0.05) respectively, versus nADSCs.
Furthermore, in treated cells with 150 and 300 lM concen-
trations DFO, expression levels of SDF-1 were estimated
to be in the order of 0.32  0.01 times (P < 0.01) and
0.68  0.9 times (P > 0.05) respectively versus nADSCs.
FGF-2 expression was estimated in both 150 and 300 lM
concentrations of DFO-treated diabetic ADSCs to be in the
order of 0.47  0.08 times (P < 0.05) versus nADSCs.
Notably, VEGF expression was higher at 300 lM concen-
tration of DFO-treated dADSCs compared to normal cells.
SDF-1 expression was enhanced at 300 lM concentration
of DFO so that non-significant change was detected
between normal ADSCs and 300 lM DFO-treated ADSCs.
On the other hand, treatment with DFO did not promote
expression of FGF-2 to reach the normal level (Fig. 5a).
Promotion of VEGF protein secretion by DFO
To investigate effects of DFO on VEGF protein release,
ELISA was performed on CM derived from ADSCs.
(a) (b)
(c) (d)Figure 3. Effect of DFO on proliferation of
ADSCs. (a) Viability of diabetic cells signifi-
cantly was lower than viability of normal
ADSCs after 72 h measured by MTT assay.
Diabetic ADSCs were treated with 75 lM (b),
150 lM (c) and 300 lM (d) of DFO for 24,
48 and 72 h and their viability was measured
by MTT assay. Data are represented as mean
 SEM (n = 5; *P < 0.05, **P < 0.01,
***P < 0.001 versus normal cells). Statistical
significance was measured by repeated mea-
sures ANOVA.
(a)
I
II
II
I
(b)
Figure 4. Effect of DFO on HIF-1a expression at protein level. (a) Representative blot (I) and semi-quantitative data (II) of HIF-1a expression
at protein level in normal and diabetic ADSCs and treated dADSCs at different concentrations of DFO after 24 h. (b) Representative blot (I) and
semi-quantitative data (II) of HIF-1a expression at protein levels in treated dADSCs with DFO (150 lM) after different times. Data are represented
as mean  SEM (n = 3; *P < 0.05, ***P < 0.001 versus normal cells and ##P < 0.01, ###P < 0.001 versus diabetic cells and xxxP < 0.001 versus
300 lM DFO-treated dADSCs). Statistical significance measured by one-way ANOVA.
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Secretion of VEGF in CM of dADSCs was significantly
lower than that obtained from nADSCs (P < 0.001), and
secretion of VEGF in CM was significantly enhanced
by 150 (P < 0.01) and 300 lM (P < 0.001) DFO com-
pared to non-treated dADSCs, cells in a concentration-
dependent manner. VEGF secretion was restored at
300 lM concentration of DFO (P < 0.01). This effect
was reversed by the use of HIF-1 inhibitor (P < 0.001;
Fig. 5b).
DFO promoted FGF-2 and SDF-1 protein expression
levels
Translation of FGF-2 and SDF-1 genes to protein was
determined by western blot assay. In nADSCs, expres-
sion of FGF-2 (P < 0.001) and SDF-1 (P < 0.001)
genes was higher than dADSCs and level of SDF-1 pro-
tein was enhanced at 300 lM concentration of DFO
(P < 0.001) compared to dADSCs. Treatment with DFO
(150 and 300 lM) promoted expression of FGF-2 so that
non-significant change was detected between nADSCs
and treated dADSCs. The elevating effect of DFO on
FGF-2 (P < 0.001) and SDF-1 (P < 0.001) protein
expression was significantly reversed by use of HIF-1
inhibitor (Fig. 5c).
DFO promoted MMP-2 and -9 activity in diabetic
ADSCs
MMP-2 and MMP-9 enzyme activities were assessed by
gelatin zymography. CM collected from cultured
nADSCs had significantly higher levels of zymographic
activity than of dADSCs, for MMP-2 and for MMP-9
(P < 0.001). DFO significantly increased enzyme activ-
ity of MMP-2 and MMP-9 compared to dADSCs
(150 lM; P < 0.001 and 300 lM; P < 0.001). Notably,
(a)
I
II
III
(b)
(c)
Figure 5. Effect of DFO on angiogenic gene expression. (a) Diabetic ADSCs were exposed to DFO (150 and 300 lM) for 24 h and mRNA
expression levels of VEGF (a), SDF-1(b) and FGF-2 (c) genes determined by qRT-PCR. (b) Secretion measurement of VEGF in CM of ADSCs
after treatment with DFO by ELISA assay. (c) Representative blots and semi-quantitative data of SDF-1 and FGF-2 expression at protein levels in
non-treated and treated ADSCs with different concentrations of DFO after 24 h. Data are represented as mean  SEM (n = 3; *P < 0.05,
**P < 0.01, ***P < 0.001 versus normal cells and #P < 0.05, ##P < 0.01, ###P < 0.001 versus diabetic cells and xxxP < 0.001 versus 300 lM
DFO-treated dADSCs). Statistical significance measured by one-way ANOVA.
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enzyme activity of MMP-2 and -9 of CM derived from
300 lM concentration of DFO-treated dADSCs was sim-
ilar to those derived from normal cells (Fig. 6).
Migration increased with conditioned medium derived
from DFO pre-treated cells
CM derived from normal (P < 0.001), 150 lM
(P < 0.01) and 300 lM (P < 0.001) DFO-treated
dADSCs remarkably increased migration of HUVECs in
comparison with CM derived from non-treated dADSCs.
Potentials of CM derived from 150 and 300 lM DFO-
treated ADSCs to promote migration were similar to
those derived from normal cells. Non-significant changes
in migration rate were detected between CM derived
from diabetic group and serum-free medium (Fig. 7a,b).
DFO enhanced tube formation in a three-dimensional
model of angiogenesis
CM derived from nADSCs (P < 0.001) and 300 lM
(P < 0.01) DFO-treated ADSCs had significantly higher
levels of endothelial cell sprout formations compared to
CM derived from dADSCs. The potential of CM
derived from 300 lM DFO-treated ADSCs to promote
sprout formation was similar to that derived from
normal cells. Hence, DFO was applied at concentrations
of 300 lM for evaluating effects of CM derived from
DFO-treated diabetic ADSCs on wound healing
(Fig. 7c,d).
Effect of CM derived from DFO pre-treated diabetic
ADSCs on wound closure
On the first day, mean wound area was
51.45  0.12 mm2. Analysis showed that there were no
remarkable differences in primary wound area between
the four groups (P > 0.05). A two-way analysis of vari-
ances showed that wounds injected with CM derived
from normal (normal ADSC group; P < 0.05) and
300 lM DFO-treated ADSCs (DFO-treated ADSC
group; P < 0.05) showed significantly higher levels of
wound closure rate compared to those injected with CM
derived from dADSCs and FBS-negative medium
(Fig. 8a,b). Analysis with Duncan and Bonferroni post-
testing also showed that wound closure rate increased in
all groups over 14 days, so that wound closure rate in
groups injected with CM derived from normal or
300 lM DFO-treated ADSCs was significantly higher
than those injected with CM derived from dADSC
groups after 10 days (P < 0.05).
Effect of CM derived from DFO pre-treated diabetic
ADSCs on angiogenesis in wounds
Two-way ANOVA testing indicated that there was a sig-
nificant effect of time (P < 0.001) and treatments
(P < 0.001) on angiogenesis in wounds. It was shown
that interaction between time and groups was significant
in all parameters (P < 0.001), so that groups injected
with CM derived from normal and 300 lM DFO-treated
ADSCs had significantly higher levels of angiogenesis
compared to those injected with CM derived from
dADSCs groups (P < 0.001). However, non-significant
differences in angiogenesis were detected between
wounds injected with CM from normal and DFO-treated
ADSCs, or between those injected with CM derived
from dADSCs and FBS-free medium (P > 0.001). Anal-
ysis with Duncan post-testing also showed that angio-
genesis significantly increased over the first 3 days and
reached its maximum level after 7 days. It then
decreased by days 10 and 14 in all groups. Analysis by
Bonferroni post-testing also showed that angiogenic
activity of CM derived from normal or 300 lM DFO-
treated ADSCs was significantly (P < 0.001) higher than
CM derived from dADSCs on 3 and 7 days, and non-
significant differences were observed between groups
regarding angiogenesis on days 10 and 14 (Fig. 9a,b).
Figure 6. Assessment of gelatinases by gelatin zymography in
ADSCs. Representative zymogram (a) and semi-quantitative data of
MMP-2 (b) and MMP-9 (c) activity in conditioned media derived from
nADSCs, DFO-treated and non-treated dADSCs. The areas of protease
activity appeared as white bands. Data are represented as mean 
SEM. Data are represented as mean  SEM (n = 3; **P < 0.01,
***P < 0.001 versus normal cells and ###P < 0.001 versus diabetic
cells and xxxP < 0.001 versus 300 lM DFO-treated dADSCs). Statisti-
cal significant differences by one-way ANOVA.
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Effect of CM derived from DFO pre-treated diabetic
ADSCs on collagenization and epitheliarization
Two-way ANOVA testing indicated that there was a sig-
nificant effect of time (P < 0.001) and treatments
(P < 0.001) on collagenization and epitheliarization of
wounds in all groups. It was shown that groups which
were injected with CM derived from normal and 300 lM
DFO-treated ADSCs had significantly higher levels of
collagenization and epitheliarization compared to those
injected with CM derived from dADSC groups
(P < 0.001). Epitheliarization also was enhanced in all
groups over the 14 days experimentation (P < 0.001).
Groups treated with CM derived from normal and DFO-
treated cells compared to those injected with CM derived
from dADSCs had higher levels of epitheliarization, so
that differences between CM derived from normal or
300 lM DFO-treated ADSCs and CM derived from
dADSCs were significant after 10 days (P < 0.001). On
day 14, wounds of all groups were fully epitheliarized but
in groups injected with CM derived from dADSCs, scabs
covered wounds until day 14; otherwise scabs were not
seen in wounds injected with CM derived from treated
group (Fig. 10; Table 3). Collagen levels also increased
after 3 days and reached to maximum levels by 10 days
then reduced in all groups. Collagen levels were signifi-
cantly (P < 0.001) higher in groups injected with CM
derived from normal and DFO-treated ADSCs compared
to those treated with CM derived from dADSC groups
(P < 0.001; Fig. 11; Table 3). There was no significant
difference in macrophage count between any groups
during the study (P > 0.05; Table 3).
Discussion
Over the last decade, cell therapy based on ADSCs has
emerged as an appealing approach for promoting angio-
genesis in ischaemic tissues (12). However, diseases
affecting vasculature can inversely influence therapeutic
(a)
(b)
(c)
(d)
I II III IV V I II III
IV V
Figure 7. Assessment of angiogenic potential of conditioned media derived from ADSCs. (a) Representative image of migration of HUVECs
cultured in different media (I) medium without FBS, (II) CM derived from normal ADSCs, (III) diabetic ADSCs, (IV) 150 lM and (V) 300 lM
DFO-treated ADSCs by inverted microscopy after 24 h. (b) Assessment of areas free of HUVECs by NIH image software, in five separated fields.
(c) Sprout formation of HUVECs in (I) serum-free medium, (II) CM derived from nADSCs, (III) dADSCs, (IV) 150 lM and (V) 300 lM DFO-trea-
ted dADSCs were monitored by inverted microscopy after 48 h. (d) Change in sprout formation of HUVECs determined by NIH image. Data repre-
sented as mean  SEM (n = 3; **P < 0.01, ***P < 0.001 versus normal cells and ##P < 0.01, ###P < 0.001 versus diabetic cells). Statistical
significance measured by one-way ANOVA.
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potential of autologous ADSCs utilized in cell therapy
(34,35). Hence, for enhancing angiogenesis, pre-treat-
ment strategies are required to revive normal function of
autologous ADSCs before transplantation. To date,
hypoxia preconditioning has been considered a desirable
approach to enhance survival and therapeutic neovascu-
larization capacity of implanted cells (23,36). Interest-
ingly, pharmacological agents mimicking hypoxia have
been found to be used more easily and economically to
restore impaired angiogenic mechanisms (24). In the
current study, for the first time, we employed a pharma-
cological preconditioning approach based on targeting
HIF-1a to restore hampered cell functions of ADSCs,
under diabetic conditions. First, proliferative capacity as
well as angiogenic gene profiles of dADSCs were exam-
ined compared to healthy controls. The current results
Figure 8. Assessment of rat wound closure
rate after treatment with different condi-
tioned media derived from ADSCs. Follow-
ing creating 8 mm full-thickness excisional
skin wounds, wounds were injected with
100 ll concentrated medium and concentrated
CM derived from ADSCs. Yellow dash lines
indicate margins of primary wounds. (a) Rep-
resentative gross picture of healing process of
wounds injected with conditioned media
derived from non-treated diabetic ADSCs
(control) and 300 lM DFO-treated dADSCs
(DFO-treated) after 0, 7, 10, 12 and 14 days.
(b) Quantification of wound closure rate in all
groups using NIH ImageJ software. CM
derived from normal and 300 lM DFO-treated
ADSCs significantly increased wound healing
rates compared to CM derived from dADSC
groups over 10 days. Data are represented as
mean  SEM. (n = 3; *P < 0.05, **P < 0.01
versus normal cells, #P < 0.05 versus diabetic
cells). Statistical significance by two-way
ANOVA.
(a)
I II III IV
V VI VII VIII
(b)
Figure 9. Assessment of rat wound angio-
genesis after treatment with different con-
ditioned media derived from ADSCs. (a)
Haematoxylin and eosin-stained histological
sections for assessment of angiogenesis in
wounds treated with serum-free medium
(I&V), CM derived from (II&VI) nADSCs,
(III&VII) dADSCs and (IV&VIII) 300 lM
DFO-treated dADSCs are shown after 3 and
7 days respectively. Arrows denote blood
vessels. (b) Comparison between angiogenic
scores in groups after 3 and 7 days. Data are
represented as mean  SEM. (n = 3;
***P < 0.001 versus normal cells). Statistical
significance measured by two-way ANOVA.
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(a) (b)
(c) (d)
Figure 10. Effect of CM derived from
DFO pre-treated cells on epitheliarization.
Epitheliarization was evaluated using histo-
logical analysis after H&E staining at x100
magnification by light microscopy. Arrows
denote epithelium. Wounds injected with con-
ditioned media derived from normal ADSCs
(b) and 300 lM DFO-treated diabetic ADSCs
(d) had higher tissue epitheliarization com-
pared to those injected with CM derived from
serum-free medium (a) and non-treated dia-
betic ADSCs (c).
Table 3. Histological findings between groups. Collagen, epithelialization and macrophage assessment of wounds injected with serum-free medium
and different conditioned media
Parameter Groups Treatment days
Mean  SEM
Day 3 Day 7 Day 10 Day 14
Collagen Serum-free mediuma 0.0  0.0 1.0  0.0 1.5  0.1*** 1.5  0.1
Normalb 0.0  0.0 1.3  0.1 2.7  0.1 1.6  0.1
Diabeticc 0.0  0.0 1.1  0.1 1.7  0.1*** 1.3  0.1
DFO treatedd 0.0  0.0 1.4  0.1 2.5  0.1 1.5  0.1
Epithelialization Serum-free medium 0.0  0.0 0.6  0.3 1.3  0.5*** 2.6  0.3
Normal 0.0  0.0 0.6  0.3 3.0  0.0 3.0  0.0
Diabetic 0.0  0.0 0.6  0.3 1.3  0.5*** 3.0  0.0
DFO treated 0.0  0.0 1.0  0.0 2.6  0.5 3.0  0.0
Macrophage Serum-free medium 0.8  0.4 1.6  0.5 1.7  0.5 1.0  0.0
Normal 1.0  0.0 1.6  0.5 1.8  0.4 0.8  0.4
Diabetic 0.7  0.5 1.8  0.4 1.8  0.4 1.4  0.5
DFO treated 0.8  0.4 1.8  0.4 1.6  0.5 1.6  0.5
Data are represented as mean  SEM (n = 3; ***P < 0.001 versus normal group).
aGroups injected with serum-free medium.
bGroups injected with conditioned medium derived from normal ADSCs.
cGroups injected with conditioned medium derived from non-treated diabetic ADSCs.
dGroups injected with conditioned medium derived from 300 lM DFO-treated ADSCs
© 2015 John Wiley & Sons Ltd Cell Proliferation, 48, 532–549
544 M. Mehrabani et al.
seem to indicate that proliferative possibility of dADSCs
was lower than normal cells, at similar passages. More-
over, in the CFU test, colonies derived from dADSCs
were remarkably smaller and fewer than from nADSCs.
In agreement with us, other studies have reported signif-
icantly lower proliferation and colony formation capacity
of BMSCs obtained from diabetic rats compared to con-
trols (37,38); furthermore, similar results have been
reported for epidermal stem cells (ESCs) derived from
diabetic rats (39). In contrast, non-significant changes in
growth rate have been detected in dADSCs compared to
nADSCs of mice (40). This discrepancy could be related
to differences in experimental conditions such as dura-
tion of post-diabetes induction. Our current report has
also shown diabetic cells to display a more flattened
appearance. This morphology could be due to premature
ageing processes of dADSCs, which represent lower
proliferative capacity and also show changes at the
molecular level compared to control cells (41).
In addition to macroscopic differences, expression of
HIF-1a and its downstream angiogenic genes (VEGF,
FGF-2 and SDF-1) as well as activity of MMP-2 and
MMP-9 were significantly lower in dADSCs compared
to nADSCs. Correspondingly, conditioned medium
derived from dADSCs showed a significantly lower
potential in scratch assays, three-dimensional tube for-
mation and wound healing. Several lines of evidence are
in agreement with this report indicating significant
defects in secretion of angiogenic cytokines. such as
VEGF, from MSCs as well as impairment in expression
of other genes associated with cell survival (12,42). In
contrast, Gu and colleagues have reported non-signifi-
cant differences between angiogenic capacity of
dADSCs and nADSCs after implantation into ischaemic
skin (11). Following assessment of impaired mecha-
nisms in dADSCs, this study has tried to establish
effects of DFO on dADSCs, and to evaluate the effec-
tiveness of DFO to correct hampered mechanisms with
the goal of utilizing the cells in cell therapy for diabetic
patients. In the cell viability assay, DFO from 75 to
300 lM did not show any cytotoxic effect after 24 h.
Consistent with the current results, in a recent study per-
formed on nADSCs, DFO from 50 to 500 lM for 24 h
did not show any cytotoxic effects (13). These findings
suggest that DFO pre-treatment may be a safe pharma-
cological approach for promoting angiogenic activity of
ADSCs. These results have also demonstrated that DFO
preconditioning significantly enhanced HIF-1a expres-
sion at the protein level in a time- and concentration-
dependent manner. In agreement with this report, one
(a) (b)
(c) (d)
Figure 11. Effect of CM derived from
DFO pre-treated cells on collagenization.
Collagenization was evaluated using Mas-
son’s trichrome staining at x400 magnifica-
tion, by light microscopy. Collagen fibres are
stained blue and arrows denote collagen
fibres. Wounds injected with conditioned
media derived from normal ADSCs (b) and
300 lM DFO-treated diabetic ADSCs (d) had
higher tissue collagenization compared to
those injected with CM derived from non-
treated diabetic ADSCs (c) and serum-free
medium (a).
© 2015 John Wiley & Sons Ltd Cell Proliferation, 48, 532–549
Deferoxamine restore Angiogenesis in stem cell 545
pervious study has shown that DFO-induced expression
of HIF-1a protein in BMSCs, reached its maximum
level after 24 h (43).
The present invetsigation has also elucidated that
DFO significantly increased expression of VEGF, SDF-
1 and FGF-2 in mRNA and protein levels. Existence of
HREs at the promoter level of VEGF, SDF-1 and FGF-
2 genes is the most important possible reason for con-
cordant stabilization of HIF-1a and up-regulation of rel-
evant genes here (20,44,45). These results are supported
by work performed by Hou et al., confirming that DFO,
in a HIF-1a-dependent manner, significantly increased
expression of VEGF and SDF-1 genes in an excisional
diabetic wound model (27). Similarly, local injection of
DFO has prevented skin flap necrosis in mice by elevat-
ing expression of HIF-1a, VEGF and endothelial pro-
genitor cell (EPCs) mobilization (46). In a further study
performed by Chekanov and colleagues, DFO enhanced
expression of FGF-2 in fibroblasts and smooth muscle
cells (47). In contrast, Potier et al. showed that FGF-2
expression was non-significantly increased in DFO pre-
treated BMSCs at mRNA and protein levels (28). This
discrepancy might be due to differences in time and
concentration of DFO treatment. Moreover, these results
indicated that high compared to low concentration of
DFO (300 and 150 lM) increased expression of FGF-2
genes to a similar extent. Based on this finding, further
experiments are required to clarify whether there are
other intervening pathways that prevent the promoting
effect of DFO on FGF-2 expression.
In addition to angiogenic factors, proteolytic enzymes
also contribute to angiogenic activity of ADSCs. MSCs
secrete MMP-2 and-9, which are two pivotal members of
the MMP enzyme family. These are strongly involved in
physiological processes, including endothelial invasion
during angiogenesis (48,49), and homing processes of
stem cells (50). MMPs have been shown to increase angio-
genesis through several mechanisms including remod-
elling components of the ECM, degradation of basement
membranes, cleaving of endothelial cell–cell adhesions
and pericyte detachment from vessels (49). In the current
study, we found that DFO pre-treatment significantly pro-
moted activity of secreted MMP-2 and -9 via a HIF-1-de-
pendent pathway. These results have also been reported in
previous investigations indicating that promoter activities
of MMP-2 and -9 were HIF-1a-dependent (51,52). Najafi
et al. demonstrated that DFO remarkably enhanced MMP-
2 and -9 enzyme activity in BMSCs by a HIF-1a-mediated
mechanism (43). In contrast, one study on hepatoma cells
has shown that MMP expression is HIF-1a independent
(53). Furthermore, it must be noted that activity of these
enzymes would be adversely increased in chronic ischae-
mic areas such as diabetic wounds (54–56).
The current study has also shown that CM derived
from DFO-treated ADSCs significantly improved migra-
tion and sprout formation capacity of endothelial cells.
Along with this result, one further investigation has also
shown that hypoxic preconditioning promotes the ability
of dADSCs and nADSCs to enhance angiogenesis by
paracrine means (11,12). Conversely, Jiang and col-
leagues reported that there was no remarkable differ-
ences between numbers and lengths of tubules produced
by HUVECs treated with CM from DFO-preconditioned
and control ADSCs (13).
To investigate whether enhanced in vitro angiogenic
capacity of DFO pre-treated ADSCs contributed to
improved in vivo angiogenic paracrine potential of
ADSCs in injured tissue, we established a surgical
wound model in rats. Histological examination showed
that CM derived from normal and treated ADSCs
(300 lM DFO) significantly enhanced angiogenesis. It
has previously been shown that transplantation of MSCs
promoted angiogenesis in the wound area of diabetic
mice. This effect was predominantly mediated by para-
crine effects rather than by their direct differentiation
and incorporation in vascular walls (8). MSCs-derived
CM contain high levels of important potent angiogenic
growth factors and chemoattractants including VEGF,
FGF-2 and SDF-1 (57,58). VEGF enhances migration
and proliferation of endothelial cells (59,60). FGF-2
seems to be a crucial factor for proliferation of endothe-
lial and smooth muscle cells and development of mature
blood vessels (61). SDF-1 acts as a chemoattractant and
augments stem cell homing and vasculogenesis (62).
Furthermore, SDF-1 regulates angiogenesis through
binding to its receptors C-X-C chemokine receptor type
4 (63) and it has been observed that its deficiency con-
tributes to impaired wound healing in aged mice (64).
In addition, our current study has evaluated effects of
CM derived from ADSCs on epitheliarization, collage-
nization and wound closure rate. Results have shown that
CM derived from DFO-treated cells restored these parame-
ters by around day 10 and thus might be related to their
higher angiogenic potential compared to CM derived from
non-treated cells. It has also been reported that angiogene-
sis (which plays a key role during wound healing pro-
cesses) also influences other non-angiogenic parameters
related to wound healing (65–67). Moreover, there is a reat
deal of evidence describing a role for VEGF in accelerat-
ing wound healing through ameliorating wound closure
rate, epitheliarization and collagenization (68). However,
more experiments are required to elucidate exact mecha-
nisms involved in improving these histological findings,
by CM derived from normal or DFO-treated cells.
Moreover, current results have evaluated underlying
mechanisms involved in impairment of angiogenic
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activity of ADSCs derived from type 1 diabetic rats, and
may not be similar to other types of diabetes, including
type 2, which is commonly associated with obesity. It
has been shown that adipose tissues form obese humans
and mice are poorly oxygenated which leads to induc-
tion of HIF-1a in tissues (69–71). Hence, in contrast to
our results, HIF-1a and its downstream pathways might
be activated in poorly oxygenated adipose tissues from
type 2 diabetic patients. However, on the other hand, it
may not occur. Botusan and colleagues have demon-
strated that hyperglycaemia can make HIF-1a more sen-
sitive to degradation and reduces its stability in hypoxia
(72). Thus, it is possible that hypoxia, presented in adi-
pose tissues of type 2 diabetic patients, was not able to
induce HIF-1 expression. Hence, further research is
needed to clarify these mechanisms in type 2 diabetes.
In conclusion, these results may provide a reliable
approach for pharmacological preconditioning prior to
clinical application of ADSCs derived from patients with
type 1 diabetes, to revive their normal therapeutic value.
It could also be concluded that HIF-1a may act as an
important and key mediator in the effect of DFO to up-
regulate pivotal angiogenic genes and therefore restore
impaired mechanisms in ADSCs from rats with type 1
diabetes.
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